PF-3716556, also known as TAK-659, is a selective and orally available inhibitor of the protein kinase BTK (Bruton's Tyrosine Kinase), which plays a crucial role in the activation of B-cell receptors. This product has been gaining attention from both scientists and pharmaceutical companies due to its potential health benefits. The chemical name of PF-3716556 is 2-fluoro-N-[3-(1-methyl-2-piperidinyl)-1H-pyrazol-5-yl]-5-[(4-methyl-1,3-thiazol-5-yl)methyl]benzamide.
Chemical name: The chemical name of PF-3716556 is 2-fluoro-N-[3-(1-methyl-2-piperidinyl)-1H-pyrazol-5-yl]-5-[(4-methyl-1,3-thiazol-5-yl)methyl]benzamide.
Molecular formula: The molecular formula of PF-3716556 is C24H26FN5O2S.
Formula weight: The formula weight of PF-3716556 is 469.56 g/mol.
CAS No: The CAS number of PF-3716556 is 928774-43-0.
Top ten keywords from Google and Synonyms:
Synonyms: TAK-659, 2-Fluoro-N-(3-(1-methyl-2-piperidinyl)-1H-pyrazol-5-yl)-5-((4-methyl-1,3-thiazol-5-yl)methyl)benzamide.
Health benefits of this product: PF-3716556 may have several health benefits, including improving immune system regulation by targeting the activity of BTK, which can help treat chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma, and other autoimmune disorders.
Potential effects: PF-3716556 acts as a selective inhibitor of BTK, leading to the inhibition of B-cell receptor signaling, which plays a critical role in the development of CLL and non-Hodgkin's lymphoma. By inhibiting the activity of BTK, PF-3716556 can reduce cell proliferation and increase apoptosis, leading to the death of cancer cells. Additionally, it has shown promise in treating rheumatoid arthritis and other autoimmune disorders.
Product mechanism: PF-3716556 works by selectively inhibiting the activity of BTK, which plays a crucial role in the activation of B-cell receptors. By blocking the activity of BTK, PF-3716556 can prevent the activation of downstream signaling pathways, leading to reduced cell proliferation and increased apoptosis in cancer cells.
Safety: While PF-3716556 has shown promising results in preclinical studies, it is still undergoing testing to confirm its safety and efficacy. At present, there are no FDA-approved drugs containing PF-3716556.
Side effects: As with any medication, some side effects may occur when taking PF-3716556. However, it has shown good tolerability in clinical trials, with most adverse effects being mild to moderate in severity.
Dosing information: The dosage of PF-3716556 will vary depending on the condition being treated, the patient's age, and other factors. Currently, there is no recommended dose for PF-3716556, as it is not yet approved for medical use.
Conclusion: In conclusion, PF-3716556 is a promising new product that offers significant potential health benefits for various diseases associated with B-cell receptor signaling and immune system regulation. It works by selectively inhibiting the activity of BTK, which is critical for the survival and proliferation of cancer cells. While more research is necessary to confirm its efficacy and safety, early studies show promise. With continued research, PF-3716556 may provide valuable insights into the potential uses of BTK inhibitors and how they can be used to improve human health
